Lab or animal research
P021 primary study · PMID 28655344
Female3xTg-AD mice and wild-type controls; behavioral and tissue-analysis groups separate.
Reported findings. Improved spatial/object-location memory and selected neurogenesis, dendritic and synaptic markers were reported.
Nonresponse. Nine-month MAP2 deficit was not prevented; cortical synaptophysin active-versus-vehicle difference was nonsignificant.
Harms. Authors report no weight loss, tumors or signs of pain during approximately18months in mice; no human safety assessment.
Limits. P21/P021 equivalence unresolved. Long preventive mouse treatment does not establish human efficacy or route transfer.
Preparation: Experimental P021: CNTF-derived DGGL with adamantylated glycine, N-terminal acetylation and C-terminal amide; not a verified generic P21 preparation. Route: Oral mouse-feed exposure from age3 through21months; not a human or nasal outcome.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.